Business Context and Reporting Period
Company: uniQure N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: June 17, 2026
Reporting Period: Event-based report regarding regulatory progress for the candidate drug AMT-130.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Events
- BLA Submission Plan: The Company announced plans to submit a Biologic License Application (BLA) for AMT-130 (for Huntington's Disease) during the third quarter of 2026.
- FDA Alignment: Following a Type B meeting with the U.S. Food and Drug Administration (FDA), the agency indicated that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis for accelerated approval.
- Confirmatory Study Design: Prior to BLA submission, the FDA seeks alignment on a confirmatory study design. This includes consideration of a concurrent control of standard of care that would not include a sham procedure.
- Timeline: The Company expects to receive final minutes from the Type B meeting within 30 days and is committed to conducting the confirmatory study without delay.
Guidance, Outlook, and Risks
Outlook: Management expects to align with the FDA on confirmatory study details prior to BLA submission and aims for accelerated approval of AMT-130.
Risks and Contingencies: The filing includes extensive forward-looking statements with significant risks, including:
- Failure of Phase I/II trial data to support a BLA or accelerated approval.
- Regulatory authorities requiring different interpretations of data or additional patient data.
- Challenges in designing, funding, or successfully completing the required confirmatory study.
- Potential post-approval requirements that may be difficult or costly to satisfy.
- General risks related to gene therapy development, intellectual property, and capital raising.
Investor Verification Checklist
- Verify the final minutes of the FDA Type B meeting once released (expected within 30 days of June 17, 2026).
- Confirm the specific design of the confirmatory study, particularly the control arm structure (standard of care vs. sham).
- Monitor the Company's ability to secure funding for the confirmatory study and ongoing operations.
- Review the Company's most recent Form 10-Q (filed May 5, 2026) and Form 10-K (filed March 2, 2026) for detailed risk factors and financial status.
- Track the actual submission date of the BLA in Q3 2026 against the announced timeline.